MiniMed Flex Pump Gains Share as MiniMed Raises Guidance
MiniMed’s Flex insulin pump is accelerating sales after late-June shipments, with US revenue up 13.1% and new pump sales rising more than 20% year over year as conversions from rival systems double. Western Europe demand is improving as Simplera sensor output triples, lifting UK pump sales 50% and France 20%. MiniMed also filed a 510(k) for its Fit patch pump and saw Vivera trial results with 74% time in range; full-year organic growth guidance rises to about 10.5%, despite $111M separation and standup costs.